Salvage Therapy with 225Ас-PSMA in Third-Line Radionuclide Therapy in Patient With Anemia and Thrombocytopenia
https://doi.org/10.37174/2587-7593-2024-7-4-93-99
Abstract
Metastatic castration-resistant prostate cancer (mCRPC) is the final stage of this disease. Modern approaches to the treatment of the mCRPC patients include a wide range of drugs (hormonal therapy, chemotherapy, PARP inhibitors, radionuclide therapy with the osteotropic drug radium chloride 223Ra and target radioligands (177Lu-PSMA and 225Ac-PSMA). The clinical example presented in the article shows the consistent application of various methods (lines) of radionuclide therapy in the treatment of a mCRPC patient. The possibility of successful use of radioligand therapy 225Ac-PSMA in patients with significantly reduced hematological parameters against the background of a significant increase in the level of PSA.
About the Authors
T. Yu. Kochetova
A.F. Tsyb Medical Radiological Research Centre — branch of the National Medical Research Radiological Centrе
Russian Federation
Competing Interests:
Russian Federation
Tatyana Yu. Kochetova
4, Korolyova str., Obninsk, Russia 249036
Competing Interests:
Conflict of interests. Not declared
A. A. Zheleznov
A.F. Tsyb Medical Radiological Research Centre — branch of the National Medical Research Radiological Centrе
Russian Federation
Competing Interests:
Russian Federation
4, Korolyova str., Obninsk, Russia 249036
Competing Interests:
Conflict of interests. Not declared
V. V. Krylov
A.F. Tsyb Medical Radiological Research Centre — branch of the National Medical Research Radiological Centrе
Russian Federation
Competing Interests:
Russian Federation
4, Korolyova str., Obninsk, Russia 249036
Competing Interests:
Conflict of interests. Not declared
M. A. Sigov
A.F. Tsyb Medical Radiological Research Centre — branch of the National Medical Research Radiological Centrе
Russian Federation
Competing Interests:
Russian Federation
4, Korolyova str., Obninsk, Russia 249036
Competing Interests:
Conflict of interests. Not declared
E. A. Sidorenko
A.F. Tsyb Medical Radiological Research Centre — branch of the National Medical Research Radiological Centrе
Russian Federation
Competing Interests:
Russian Federation
4, Korolyova str., Obninsk, Russia 249036
Competing Interests:
Conflict of interests. Not declared
S. A. Ivanov
A.F. Tsyb Medical Radiological Research Centre — branch of the National Medical Research Radiological Centrе
Russian Federation
Competing Interests:
Russian Federation
4, Korolyova str., Obninsk, Russia 249036
Competing Interests:
Conflict of interests. Not declared
References
1. irby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65(11):1180-92. https://doi.org/10.1111/j.1742-1241.2011.02799.x. PMID: 21995694
2. Markova AS, Matveev VB, Nazranov BM. Sequential therapy of metastatic castration-resistant prostate cancer: new possibilities. Onkourologiya с Cancer Urology 2018; 14(3):120-7 (In Russ.). https://doi.org/10.17650/1726-9776-2018-14-3-120-127
3. Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021;385(12):1091-103. https://doi.org/10.1056/NEJMoa2107322
4. Chi KN, Armstrong AJ, Krause BJ, et al. Safety Analyses of the Phase 3 VISION Trial of [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2024;85(4):382-91. https://doi.org/10.1016/j.eururo.2023.12.004
5. Kratochwil C, Haberkorn U, Giesel FL. 225Ac-PSMA-617 for Therapy of Prostate Cancer Semin Nucl Med. 2020;50(2):133-140. doi: 10.1053/j.semnuclmed.2020.02.004. Epub 2020 Feb 14. PMID: 32172798
6. Scher HI, Morris MJ, Stadler WM, et al. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016;34(12):1402-18. https://doi.org/10.1200/JCO.2015.64.2702
7. Kochetova TYu, Krylov VV, Sigov MA, et al. A Pilot Safety Study of Increased Activities (Doses) of 225Ac-PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer. Journal of Oncology: Diagnostic Radiology and Radiotherapy. 2024;7(1):30-40. (In Russ.). https://doi.org/10.37174/2587-7593-2024-7-1-30-40
8. Ahmadzadehfar H, Matern R, Baum RP, et al. The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [177Lu]Lu-PSMA-617: a WARMTH multicentre study. Eur J Nucl Med Mol Imaging. 2021;48(12):4067-76. https://doi.org/10.1007/s00259-021-05383-3
Review
For citations:
Kochetova T.Yu., Zheleznov A.A., Krylov V.V., Sigov M.A., Sidorenko E.A., Ivanov S.A. Salvage Therapy with 225Ас-PSMA in Third-Line Radionuclide Therapy in Patient With Anemia and Thrombocytopenia. Journal of oncology: diagnostic radiology and radiotherapy. 2024;7(4):93-99. (In Russ.) https://doi.org/10.37174/2587-7593-2024-7-4-93-99
Views:
179
Email this article 